If administered sufficiently early in the course of the disease, the MAPT-ASOs described here might be useful for limiting the initiation and spreading of tau pathology in AD in a more targeted manner compared to approaches aimed at global tau depletion. This evidence concerns the gene MAPT and Alzheimer disease.